Samples are submitted through Nesiller Genetic to Foundation Medicine’s laboratories in the United States, where they are analyzed using an FDA-approved comprehensive genomic profiling (CGP) platform.
Key Features:
| Feature | FoundationOne® CDx | FoundationOne® Liquid CDx | FoundationOne® RNA |
|---|---|---|---|
| Intended Use | Comprehensive genomic profiling for all solid tumors (Gold Standard) | Minimally invasive comprehensive genomic profiling and complementary analysis when tissue biopsy is limited or unavailable | Analysis of clinically relevant RNA alterations |
| Sample Type | FFPE Tissue | Peripheral Whole Blood (2 Streck Tubes) | FFPE Tissue |
| Analysis | 324 Genes + MSI + TMB + HRD | 324 Genes + MSI-H + bTMB* | 318 Genes (RNA Fusion Analysis) |
| Variant Types | SNVs, Indels, CNAs, Rearrangements | SNVs, Indels, CNAs, Copy Number Loss (CNL), Rearrangements | Fusions, Rearrangements, Splice Variants |
| Additional Features | Optional PD-L1 IHC | Tumor Fraction Reporting | Integrated DNA + RNA Report |
| Turnaround Time | Approximately 2 weeks | Approximately 2 weeks | Approximately 2 weeks |
* bTMB: Blood Tumor Mutational Burden.
19 Mayıs Mah. Çoruh Sok. No:32/1 Fulya, Şişli / Istanbul, Turkey
Monday - Friday 09:00 - 18:00 Saturday 09:00 - 14:00